Magnesium supplementation to lower high blood pressure
Trial of Magnesium Supplementation and Blood Pressure Reduction Among Adults with Elevated Systolic Blood Pressure
This study is testing if taking magnesium supplements can help lower high blood pressure in adults aged 30 to 74 over 12 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 30 Years to 74 Years |
| Sex | All |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05690464 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of magnesium glycinate supplementation at a dosage of 480 mg per day over a 12-week period in reducing systolic blood pressure in adults aged 30-74 with elevated blood pressure levels. Participants will undergo a two-stage screening process to determine eligibility, followed by random assignment to either the magnesium supplement or a placebo group. Assessments will include blood pressure measurements, body metrics, and health questionnaires at both the screening and 12-week follow-up visits.
Who should consider this trial
Good fit: Ideal candidates are adults aged 30-74 with a systolic blood pressure between 130-154 mmHg and a body mass index under 40 kg/m2.
Not a fit: Patients with a history of cardiovascular disease, diabetes, renal disease, or certain gastrointestinal conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a simple and effective dietary intervention for managing elevated blood pressure.
How similar studies have performed: Previous studies have suggested that magnesium supplementation may help lower blood pressure, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Self-report of systolic blood pressure 125-159 mmHg * Measured seated systolic blood pressure 130-159 mmHg at screening visit * Body mass index less than 40 kg/m2 * Total magnesium intake from supplements of no more than 100 mg/day * Willing to maintain current diet and supplement use patterns during the 12-week intervention period Exclusion Criteria: * Measured seated diastolic blood pressure 100 mmHg or greater at screening visit * Antacid or laxative use 4 times/week or more within the past 3 months * History of cardiovascular disease (myocardial infarction, stroke, revascularization \[coronary artery bypass graft or percutaneous transluminal coronary angioplasty\], or angina pectoris) * History of invasive cancer diagnosed within the last 5 years (non-melanoma skin cancer permitted) * History of type 1 or 2 diabetes * History of renal disease * History of kidney failure * History of dialysis * History of pancreatitis * History of inflammatory bowel disease * History of hypermagnesemia * Women who are pregnant, nursing, or intend to become pregnant during the period of treatment * Plan to relocate out of Boston area within the next year * Unwillingness and/or inability to swallow 4 pills per day * Inability to provide written informed consent
Where this trial is running
Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Howard Sesso, ScD, MPH
- Email: hsesso@bwh.harvard.edu
- Phone: 617-278-0803
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.